ICCM

News IceCure Medical to boost share price with 1-for-30 reverse split to regain Nasdaq compliance

5h ago

SEC filing ICCM Reports 89.4% Recurrence-Free Rate, 100% Cosmetic Success, FDA Clearance Drives Cryoablation Adoption

14d ago

News IceCure's (ICCM) ProSense Breast Cancer Study Meets Endpoint - Zacks Investment Research

14d ago

News IceCure Medical (ICCM) New Cryoablation System Gets FDA Nod - Zacks Investment Research

14d ago

News IceCure Medical (ICCM) Moves to Buy: Rationale Behind the Upgrade

14d ago

SEC filing ICCM Reports Q1 2026 Revenue Up 26%, N. America Sales Up 84%

21d ago

News Quant snapshot: Beachbody, Deutsche Telekom among top-rated names as IceCure Medical, Fold Holdings lag

23d ago

SEC filing ICCM Announces Special Meeting May 11 2026 to Vote Reverse Split 10-30 1 Ratio Board Recommends FOR Shareholders Record Date April 27 2026

40d ago

SEC filing ICCM Reports $12M U.S. ProSense Revenue, +30% YoY, FDA Clearance Boosts Cryoablation Momentum, 50% Cost Reduction Study Wins SBI Award

42d ago

News IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates

69d ago

SEC filing ICCM Reports 89.4% 5-Year Recurrence-Free Rate for ≤3cm Kidney Tumors, 83.9% General Population, ProSense® Approved in U.S./Europe, ECIO 2026 Presentation

69d ago

News IceCure appoints Meir Peleg as CFO

70d ago

SEC filing ICCM Appoints Meir Peleg CFO, Announces FDA Clearance, ProSense® Growth, Dr. Fine Medical Director

70d ago

SEC filing ICCM Reports $3.4M FY2025 Revenue, $1.3M Q4 Sales, FDA Clearance, $50M+ Canada Expansion, 30 Site ChoICE Study Launch

77d ago

SEC filing ICCM Announces FDA Approval of ChoICE Post-Market Study for ProSense Cryoablation in Low-Risk Breast Cancer, Enrolls 400 Patients Across 30 Sites, $4K Facility Reimbursement

83d ago

SEC filing ICCM Announces ASBrS 2026 Resource Guide Recommends Cryoablation for Low-Risk Breast Cancer, FDA Clearance in Oct 2025, $200M Market Potential

85d ago

News IceCure Medical Reports Independent Study Published in PLOS One Demonstrating ProSense® Cryoablation Safe and Effective in Treatment of Breast Fibroadenomas

92d ago

News SoftBank-Backed Icertis Is Said to Work With Goldman on Potential $5 Billion Sale

111d ago

News DBS Profit Misses Estimates, Bank Says Earnings This Year to Dip

113d ago

News IceCure Celebrates American Society of Breast Surgeons' (ASBrS) Proposed Breast Cancer Treatment Guidelines Which Include Cryoablation for Low-Risk Breast Cancer

125d ago

News IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above

153d ago

News IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care

153d ago

News IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances

153d ago

News IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer

156d ago

News IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes

156d ago